Imbruvica (ibrutinib)
Blood Cancers
Key Facts
About Johnson & Johnson
Founded in 1886, Johnson & Johnson operates as a multinational healthcare corporation headquartered in New Brunswick, New Jersey. The company's pharmaceutical division, Janssen, is a global leader in oncology, immunology, and neuroscience with blockbuster drugs like Stelara, Darzalex, and Remicade. J&J combines deep scientific expertise with extensive global reach, serving patients in over 175 countries while maintaining one of the industry's strongest R&D pipelines.
View full company profileAbout AbbVie
AbbVie Inc. is a research-based biopharmaceutical company formed in 2013 as a spinoff from Abbott Laboratories. The company focuses on developing and delivering innovative therapies that address some of the world's most complex and serious diseases. With a strong portfolio led by immunology treatments and a growing oncology franchise, AbbVie has established itself as a leader in specialty therapeutics with global operations and a commitment to advancing patient care.
View full company profileTherapeutic Areas
Other Blood Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Calquence (acalabrutinib) | AstraZeneca | Approved |
| Bendeka/Treanda (bendamustine) | Teva Pharmaceutical Industries | Commercial |
| Imbruvica | Royalty Pharma | Commercial |
| Internal Blood Cancer Program(s) | Chimera Bioengineering | Pre-clinical |